FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
2.07B
Enterprise Value 3
1.69B
Trailing P/E
N/A
Forward P/E 1
-7.67
PEG Ratio (5 yr expected) 1
5.45
Price/Sales (ttm)
15.74
Price/Book (mrq)
3.45
Enterprise Value/Revenue 3
12.86
Enterprise Value/EBITDA 6
-4.51

Trading Information

Stock Price History

Beta (3Y Monthly) 1.71
52-Week Change 3-31.66%
S&P500 52-Week Change 38.32%
52 Week High 314.62
52 Week Low 37.11
50-Day Moving Average 38.84
200-Day Moving Average 311.41

Share Statistics

Avg Vol (3 month) 33.98M
Avg Vol (10 day) 34.06M
Shares Outstanding 5254.63M
Float 207.98M
% Held by Insiders 11.08%
% Held by Institutions 1104.95%
Shares Short (Sep 30, 2019) 431.37M
Short Ratio (Sep 30, 2019) 47.82
Short % of Float (Sep 30, 2019) 413.67%
Short % of Shares Outstanding (Sep 30, 2019) 412.32%
Shares Short (prior month Aug 30, 2019) 429.96M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-288.86%

Management Effectiveness

Return on Assets (ttm)-27.21%
Return on Equity (ttm)-76.10%

Income Statement

Revenue (ttm)131.42M
Revenue Per Share (ttm)0.63
Quarterly Revenue Growth (yoy)107.10%
Gross Profit (ttm)76.84M
EBITDA -375.19M
Net Income Avi to Common (ttm)-442.09M
Diluted EPS (ttm)-2.13
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)575.66M
Total Cash Per Share (mrq)2.26
Total Debt (mrq)188M
Total Debt/Equity (mrq)31.33
Current Ratio (mrq)7.09
Book Value Per Share (mrq)2.36

Cash Flow Statement

Operating Cash Flow (ttm)-330.47M
Levered Free Cash Flow (ttm)-199.75M